Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
Authors:
- Adnan KastratiAKAdnan Kastrati
- Franz-Josef NeumannFNFranz-Josef Neumann
- Julinda MehilliJMJulinda Mehilli
- Robert A. ByrneRBRobert A. Byrne
- Raisuke IijimaRIRaisuke Iijima
- Heinz Joachim BüttnerHBHeinz Joachim Büttner
- Ahmed A. KhattabAKAhmed A. Khattab
- Stefanie SchulzSSStefanie Schulz
- James C. BlankenshipJBJames C. Blankenship
- Jürgen PacheJPJürgen Pache
- Jan MinnersJMJan Minners
- Melchior SeyfarthMSMelchior Seyfarth
- 14 August 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (7) , 688-696
Abstract
Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with clopidogrel is unknown. We enrolled 4570 patients with stable or unstable angina (with normal levels of troponin T and creatine kinase MB) who were undergoing PCI after pretreatment with a 600-mg dose of clopidogrel at least 2 hours before the procedure; 2289 patients were randomly assigned in a double-blind manner to receive bivalirudin, and 2281 to receive unfractionated heparin. The primary end point was the composite of death, myocardial infarction, urgent target-vessel revascularization due to myocardial ischemia within 30 days after randomization, or major bleeding during the index hospitalization (with a net clinical benefit defined as a reduction in the incidence of the end point). The secondary end point was the composite of death, myocardial infarction, or urgent target-vessel revascularization. The incidence of the primary end point was 8.3% (190 patients) in the bivalirudin group as compared with 8.7% (199 patients) in the unfractionated-heparin group (relative risk, 0.94; 95% confidence interval [CI], 0.77 to 1.15; P=0.57). The secondary end point occurred in 134 patients (5.9%) in the bivalirudin group and 115 patients (5.0%) in the unfractionated-heparin group (relative risk, 1.16; 95% CI, 0.91 to 1.49; P=0.23). The incidence of major bleeding was 3.1% (70 patients) in the bivalirudin group and 4.6% (104 patients) in the unfractionated-heparin group (relative risk, 0.66; 95% CI, 0.49 to 0.90; P=0.008). In patients with stable and unstable angina who underwent PCI after pretreatment with clopidogrel, bivalirudin did not provide a net clinical benefit (i.e., it did not reduce the incidence of the composite end point of death, myocardial infarction, urgent target-vessel revascularization, or major bleeding) as compared with unfractionated heparin, but it did significantly reduce the incidence of major bleeding. (ClinicalTrials.gov number, NCT00262054.)Keywords
This publication has 26 references indexed in Scilit:
- Bivalirudin during Primary PCI in Acute Myocardial InfarctionNew England Journal of Medicine, 2008
- Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary InterventionsJACC, 2008
- Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trialThe Lancet, 2007
- Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel PretreatmentThe ISAR-REACT 2 Randomized TrialJAMA, 2006
- ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary InterventionJACC, 2006
- Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With FibrinolyticsThe PCI-CLARITY StudyJAMA, 2005
- Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of ClopidogrelCirculation, 2004
- A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with ClopidogrelNew England Journal of Medicine, 2004
- Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)American Heart Journal, 2002
- Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction AnginaNew England Journal of Medicine, 1995